DK2488649T3 - Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder - Google Patents
Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder Download PDFInfo
- Publication number
- DK2488649T3 DK2488649T3 DK10771611.0T DK10771611T DK2488649T3 DK 2488649 T3 DK2488649 T3 DK 2488649T3 DK 10771611 T DK10771611 T DK 10771611T DK 2488649 T3 DK2488649 T3 DK 2488649T3
- Authority
- DK
- Denmark
- Prior art keywords
- mva
- virus containing
- recombinant modified
- vaccinia
- ankara
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title 1
- 206010046865 Vaccinia virus infection Diseases 0.000 title 1
- 230000037431 insertion Effects 0.000 title 1
- 238000003780 insertion Methods 0.000 title 1
- 208000007089 vaccinia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8636—Vaccina virus vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
- C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25232609P | 2009-10-16 | 2009-10-16 | |
| PCT/US2010/052929 WO2011047324A1 (en) | 2009-10-16 | 2010-10-15 | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2488649T3 true DK2488649T3 (da) | 2019-06-17 |
Family
ID=43297031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10771611.0T DK2488649T3 (da) | 2009-10-16 | 2010-10-15 | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9133480B2 (enExample) |
| EP (1) | EP2488649B1 (enExample) |
| JP (1) | JP5789263B2 (enExample) |
| AU (1) | AU2010306559B2 (enExample) |
| CA (1) | CA2777744C (enExample) |
| DK (1) | DK2488649T3 (enExample) |
| WO (1) | WO2011047324A1 (enExample) |
| ZA (1) | ZA201203551B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008142479A2 (en) * | 2006-08-25 | 2008-11-27 | The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services | Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| AU2010306559B2 (en) | 2009-10-16 | 2015-07-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . | Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| AU2015320409B2 (en) | 2014-09-26 | 2019-03-28 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Virus-based expression vectors and uses thereof |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| US20190038659A1 (en) | 2015-09-29 | 2019-02-07 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing amyotrophic lateral sclerosis |
| CA3011014A1 (en) | 2016-01-08 | 2017-07-13 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| WO2017136419A1 (en) * | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
| WO2017210181A1 (en) * | 2016-05-30 | 2017-12-07 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2019152746A2 (en) | 2018-01-30 | 2019-08-08 | Emory University | Compositions and methods for promoting immune responses to human immunodeficiency virus |
| WO2019217922A1 (en) | 2018-05-11 | 2019-11-14 | City Of Hope | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
| KR20220011685A (ko) | 2019-05-22 | 2022-01-28 | 길리애드 사이언시즈, 인코포레이티드 | Tlr7 조절 화합물과 hiv 백신의 조합 |
| CA3156346A1 (en) * | 2019-10-02 | 2021-04-08 | Bionoxx Inc. | Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof |
| EP4058058A1 (en) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Dosage regimens for vaccines |
| IL295482A (en) | 2020-02-14 | 2022-10-01 | Geovax Inc | Vaccines and their uses to induce an immune response to sars-cov2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| CA3206004A1 (en) | 2021-02-02 | 2022-08-11 | Mary Jo Hauser | Viral constructs for use in enhancing t-cell priming during vaccination |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL218318B1 (pl) | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
| EP1610816B1 (en) | 2003-03-28 | 2013-01-02 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mva virus expressing modified hiv envelope, gag, and pol genes |
| WO2008142479A2 (en) * | 2006-08-25 | 2008-11-27 | The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services | Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus |
| EP2199400A1 (en) * | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| AU2010306559B2 (en) | 2009-10-16 | 2015-07-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . | Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites |
-
2010
- 2010-10-15 AU AU2010306559A patent/AU2010306559B2/en active Active
- 2010-10-15 CA CA2777744A patent/CA2777744C/en active Active
- 2010-10-15 JP JP2012534414A patent/JP5789263B2/ja active Active
- 2010-10-15 DK DK10771611.0T patent/DK2488649T3/da active
- 2010-10-15 WO PCT/US2010/052929 patent/WO2011047324A1/en not_active Ceased
- 2010-10-15 US US13/502,205 patent/US9133480B2/en active Active
- 2010-10-15 EP EP10771611.0A patent/EP2488649B1/en active Active
-
2012
- 2012-05-15 ZA ZA2012/03551A patent/ZA201203551B/en unknown
-
2015
- 2015-08-27 US US14/837,382 patent/US9879231B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2777744C (en) | 2019-09-24 |
| ZA201203551B (en) | 2013-01-30 |
| CA2777744A1 (en) | 2011-04-21 |
| AU2010306559B2 (en) | 2015-07-16 |
| US20120263750A1 (en) | 2012-10-18 |
| EP2488649A1 (en) | 2012-08-22 |
| US20160040135A1 (en) | 2016-02-11 |
| AU2010306559A1 (en) | 2012-06-07 |
| JP2013507935A (ja) | 2013-03-07 |
| WO2011047324A1 (en) | 2011-04-21 |
| US9879231B2 (en) | 2018-01-30 |
| US9133480B2 (en) | 2015-09-15 |
| JP5789263B2 (ja) | 2015-10-07 |
| EP2488649B1 (en) | 2019-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201203551B (en) | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites | |
| DK2459715T3 (da) | Fremgangsmåde til at oprense rekombinant adamts13 og andre proteiner og sammensætninger deraf | |
| BRPI0911604A2 (pt) | vacinas de polipeptídeo de flagelina | |
| CR10571A (es) | Vacuna virica recombinante | |
| DK2585437T3 (da) | Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf | |
| DK2853265T3 (da) | Fremgangsmåder til at øge stabiliseringen af hypoxi-inducerbar faktor-1-alpha | |
| DK2310034T3 (da) | Peptider til behandling af beta-amyloidose | |
| HUE037163T2 (hu) | Hemoglobin készítmények | |
| BRPI1011400A2 (pt) | ponte provisoria melhorada | |
| DK2270818T3 (da) | Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten | |
| IL236744A0 (en) | A modified recombinant vaccinia ankara virus respiratory syncytial virus assembly | |
| DK2118292T3 (da) | Papillomavirus E2-polypeptid der anvendes til vaccination | |
| BRPI1011034A2 (pt) | vacina de gripe universal baseada no vírus ancara vaccinia modificado (mva) recombinante | |
| HUE036071T2 (hu) | Macitentánt tartalmazó terápiás készítmények | |
| DK2361135T3 (da) | Fremgangsmåde til drift af en ovn | |
| DK2879702T3 (da) | Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv) | |
| BRPI0912350A2 (pt) | circuito de interface, e, interface | |
| DK2310613T3 (da) | Forbedret brudled til stigrør | |
| EP2591700A4 (en) | HAIR TWEEZERS | |
| JP2010531899A5 (ja) | 多機能性シリコーン混合物 | |
| BRPI0912017A2 (pt) | circuito de ponte | |
| DK2582776T3 (da) | Fremgangsmåde til opdræt af ascidier | |
| DK2276850T3 (da) | Irx-2-modificeret fremstillingsfremgangsmåde | |
| DK2571902T3 (da) | Ny fremgangsmåde | |
| DK2425258T4 (da) | Fremgangsmåde til identificering af græsarter |